Anthrax Vaccine

Global Anthrax Vaccine Market to Reach US$15.6 Billion by 2030

The global market for Anthrax Vaccine estimated at US$12.9 Billion in the year 2024, is expected to reach US$15.6 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Cell-Free PA Vaccines, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$8.4 Billion by the end of the analysis period. Growth in the Live Cell Vaccines segment is estimated at 2.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 6.1% CAGR

The Anthrax Vaccine market in the U.S. is estimated at US$3.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Anthrax Vaccine Market - Key Trends & Drivers Summarized

Why Are Anthrax Vaccines Crucial in Public Health and Biodefense?

Anthrax vaccines have emerged as a cornerstone in public health and biodefense strategies due to the severe health and security risks posed by anthrax outbreaks. Caused by Bacillus anthracis, anthrax can lead to life-threatening infections in humans and animals, with the inhalational form of the disease being particularly lethal. Vaccination programs have proven effective in preventing the spread of anthrax, especially in high-risk groups such as military personnel, first responders, and individuals working in agriculture or veterinary fields. The potential use of anthrax as a bioterrorism agent has further underscored the importance of vaccines in biodefense preparedness. Governments worldwide are actively investing in the development, production, and stockpiling of anthrax vaccines to safeguard against intentional outbreaks. Public health campaigns have also focused on raising awareness about the importance of vaccination in at-risk communities, leading to an increase in vaccine coverage and market demand. These factors collectively highlight the critical role of anthrax vaccines in protecting global health and security.

What Advances Are Driving Innovation in Anthrax Vaccine Development?

The anthrax vaccine market has seen significant advancements in vaccine development, with a strong emphasis on improving safety, efficacy, and accessibility. Traditional anthrax vaccines, such as BioThrax (AVA), rely on cell-free filtrates containing protective antigens. While effective, these vaccines often require multiple doses and booster shots, which can limit compliance and scalability. Recent innovations have focused on developing next-generation vaccines that reduce the number of doses, improve immunogenicity, and minimize adverse effects. Recombinant DNA technology has enabled the creation of vaccines that target specific anthrax antigens, enhancing their ability to elicit a robust and long-lasting immune response. Adjuvants, which are substances added to vaccines to boost their effectiveness, have also been incorporated into new formulations to improve potency and reduce dosing schedules. Additionally, researchers are exploring nasal and oral vaccine delivery systems to simplify administration and expand accessibility, particularly in remote or resource-limited areas. These technological advancements are transforming the anthrax vaccine landscape, addressing unmet needs, and driving market growth.

How Are Regional Dynamics Influencing the Anthrax Vaccine Market?

Regional variations in anthrax prevalence, public health infrastructure, and government policies have a significant impact on the anthrax vaccine market. North America leads the market, driven by strong governmental support for biodefense programs and substantial investments in research and development. The U.S. Department of Health and Human Services (HHS) has been a major purchaser of anthrax vaccines, maintaining strategic national stockpiles to prepare for potential bioterrorism incidents. Europe follows closely, with robust public health systems and stringent regulations supporting the adoption of anthrax vaccination programs. In contrast, the Asia-Pacific region is emerging as a high-growth market due to its large agricultural base, frequent zoonotic outbreaks, and improving healthcare infrastructure. Countries like China and India are ramping up vaccine production and distribution to address both human and animal health concerns. Africa and Latin America, where anthrax remains endemic in certain regions, are also witnessing increased vaccine adoption, supported by global initiatives to enhance access to immunization in low- and middle-income countries. These regional dynamics reflect the global importance of anthrax vaccines in safeguarding both public health and agricultural economies.

What Is Driving Growth in the Anthrax Vaccine Market?

The growth in the anthrax vaccine market is driven by several factors, including increasing government investments in biodefense, advancements in vaccine technologies, and rising awareness of zoonotic diseases. The development of next-generation vaccines with improved safety profiles, reduced dosing schedules, and innovative delivery methods has significantly expanded their appeal. Rising incidences of anthrax outbreaks in livestock-dense regions have further bolstered demand for vaccines in the agricultural sector, emphasizing the importance of protecting both human and animal populations. Consumer awareness of the risks associated with anthrax exposure, coupled with public health initiatives aimed at improving vaccine coverage, has contributed to increased adoption. Additionally, advancements in manufacturing technologies have enabled scalable production of vaccines, ensuring their availability during emergencies. Regional efforts to strengthen healthcare infrastructure and the global focus on biodefense preparedness have also fueled market growth, positioning anthrax vaccines as a critical component in addressing global health and security challenges.

SCOPE OF STUDY:

The report analyzes the Anthrax Vaccine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Cell-Free PA Vaccines, Live Cell Vaccines); Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels); Application (Animals Application, Humans Application)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Bavarian Nordic
• Bayer AG
• Cipla
• Colorado Serum Company
• Elusys Therapeutics Inc.
• Emergent BioSolutions
• Intervac (PVT) Ltd
• JOVAC
• MSD Animal Health
• Neuland Laboratories Ltd.
• Pfizer Inc.
• Porton Biopharma Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.